“In a prospective, multicenter study, the 31-GEP identified patients at increased risk of tumor recurrence and added significant prognostic value to AJCC staging” (2024) SKIN The Journal of Cutaneous Medicine, 8(6), p. s504. doi:10.25251/skin.8.supp.504.